AbilifyThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you your search results in order of date.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

787 records returned

Otsuka Pharmaceutical Europe Ltd Withdraws Its Application For An Extension Of Indication For Abilify (aripiprazole), EuropeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The European Medicines Agency has been formally notified by Otsuka Pharmaceutical Europe Ltd of its decision to withdraw its application for an extension of indication for the centrally authorised medicine Abilify (aripiprazole) tablets, orodispersible tablets and oral solution. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 20, 2009 Category: Consumer Health News Tags: Psychology / Psychiatry Source Type: news

Otsuka Pharmaceutical Europe Ltd Withdraws Its Application For An Extension Of Indication For Abilify (aripiprazole), EuropeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The European Medicines Agency has been formally notified by Otsuka Pharmaceutical Europe Ltd of its decision to withdraw its application for an extension of indication for the centrally authorised medicine Abilify (aripiprazole) tablets, orodispersible tablets and oral solution. Abilify was expected to be used in the treatment of major depressive episodes, as adjunctive therapy, in patients who have had an inadequate response to previous treatment with antidepressants. (Source: Mental Health News From Medical News Today)
Source: Mental Health News From Medical News Today - November 20, 2009 Category: Psychiatry Tags: Psychology / Psychiatry Source Type: news

Otsuka withdraws application for an extension of indication for aripiprazole (Abilify®) in EUEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: EMEA Area: News Otsuka Pharmaceutical Europe Ltd has informed the European Medicines of its decision to withdraw its application for an extension of indication for aripiprazole (Abilify®) tablets, orodispersible tablets and oral solution. The application had been for use in the treatment of major depressive episodes, as adjunctive therapy, in patients who have had an inadequate response to previous treatment with antidepressants. The drug is currently indicated for the treatment of schizophrenia and for the treatment and prevention of manic episodes in bipolar I disorder. The company stated that the withdrawal wa...
Source: NeLM - Mental Health - November 20, 2009 Category: Psychiatry Source Type: organizations

Effectiveness of Intramuscular Aripiprazole Injection in Patients with Catatonia: Report on Three CasesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Pharmacopsychiatry 2009; 42: 286-287DOI: 10.1055/s-0029-1224185© Georg Thieme Verlag KG Stuttgart · New YorkGet connected:Table of contents | Full text (Source: Pharmacopsychiatry)
Source: Pharmacopsychiatry - November 19, 2009 Category: Psychiatry Tags: Letter Source Type: journals

Aripiprazole: Mania?: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - November 16, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Aripiprazole/haloperidol/lithium: Movement disorders, polyuria and polydypsia, and Pisa syndrome after switching from haloperidol to aripiprazole: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - November 16, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Aripiprazole/quetiapine: Urinary bladder rupture associated with fecaloma causing sudden death: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - November 16, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Early Response to Aripiprazole May Predict Treatment Success in Adolescents With SchizophreniaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This is the first study to confirm that, as in adults, the majority of response occurs early in adolescents with schizophrenia. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 12, 2009 Category: Consumer Health News Tags: Psychiatry Source Type: news

Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Functional selectivity is the term that describes drugs that cause markedly different signaling through a single receptor (e.g., full agonist at one pathway and antagonist at a second). It has been widely recognized recently that this phenomenon impacts the understanding of mechanism of action of some drugs, and has relevance to drug discovery. One of the clinical areas where this mechanism has particular importance is in the treatment of schizophrenia. Antipsychotic drugs have been grouped according to both pattern of clinical action and mechanism of action. The original antipsychotic drugs such as chlorpromazine and ...
Source: Current Pharmaceutical Design - November 12, 2009 Category: Drugs & Pharmacology Authors: Mailman RB, Murthy V Tags: Curr Pharm Des Source Type: journals

Risperidone: Tardive parkinsonism, treated with aripiprazole: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - November 11, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Dopamine D(2)-D(3) receptor heteromers: pharmacological properties and therapeutic significance.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Heteromerization of dopamine receptors has been shown for both the D(1)/D(5) and D(2)/D(3)/D(4) receptor families, which couple positively and negatively, respectively, to adenylyl cyclase. The present article reviews data on dopamine heteromers formed by D(3), focusing in particular on associations with their D(2) counterparts. Certain antiparkinsonian agents, like the preferential and high efficacy D(3)>D(2) agonists, pramipexole, and ropinirole, show amplified potency at D(2)-D(3) heteromers versus constituent monomers. Accordingly, in cells cotransfected with D(2) and D(3) receptors, pramipexole, and ropinirole ...
Source: Current Opinion in Pharmacology - November 5, 2009 Category: Drugs & Pharmacology Authors: Maggio R, Millan MJ Tags: Curr Opin Pharmacol Source Type: journals

Methylphenidate Combined with Aripiprazole in Children and Adolescents with Bipolar Disorder and Attention-Deficit/Hyperactivity Disorder: A Randomized Crossover TrialEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Journal of Child and Adolescent Psychopharmacology Oct 2009, Vol. 19, No. 5: 553-561. (Source: Journal of Child and Adolescent Psychopharmacology)
Source: Journal of Child and Adolescent Psychopharmacology - October 30, 2009 Category: Pediatrics Tags: article Source Type: journals

Clozapine—Aripiprazole Association in a 7-Year-Old Girl with Schizophrenia: Clinical Efficacy and Successful Management of Neutropenia with LithiumEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Journal of Child and Adolescent Psychopharmacology Oct 2009, Vol. 19, No. 5: 595-598. (Source: Journal of Child and Adolescent Psychopharmacology)
Source: Journal of Child and Adolescent Psychopharmacology - October 30, 2009 Category: Pediatrics Tags: article Source Type: journals

Clozapine–Aripiprazole Association in a 7-Year-Old Girl with Schizophrenia: Clinical Efficacy and Successful Management of Neutropenia with LithiumEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Journal of Child and Adolescent Psychopharmacology Oct 2009, Vol. 19, No. 5: 595-598. (Source: Journal of Child and Adolescent Psychopharmacology)
Source: Journal of Child and Adolescent Psychopharmacology - October 30, 2009 Category: Pediatrics Tags: article Source Type: journals

Aripiprazole and Hypertension in AdolescentsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Journal of Child and Adolescent Psychopharmacology Oct 2009, Vol. 19, No. 5: 601-602. (Source: Journal of Child and Adolescent Psychopharmacology)
Source: Journal of Child and Adolescent Psychopharmacology - October 30, 2009 Category: Pediatrics Tags: article Source Type: journals

Cohort study: Cardiometabolic risk of second-generation antipsychotics during first-time use in children and adolescentsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: JAMA Area: News The results of the SATIETY cohort study have shown that first-time second-generation antipsychotic medication (aripiprazole, olanzapine, quetiapine, or risperidone) use is associated with significant weight gain in paediatric and adolescent patients. The study was conducted between December 2001 and September 2007 at semi-urban, tertiary care, academic inpatient and outpatient clinics in New York. 338 youths aged 4 to 19 years with one week or less of antipsychotic medication exposure were enrolled (66.9%). Of these, 272 had at least one post baseline assessment (80.5%), and 205 pati...
Source: NeLM - Paediatrics - October 28, 2009 Category: Pediatrics Source Type: organizations

ORIGINAL CONTRIBUTION: Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and AdolescentsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions First-time second-generation antipsychotic medication use was associated with significant weight gain with each medication. Metabolic changes varied among the 4 antipsychotic medications. (Source: JAMA)
Source: JAMA - October 27, 2009 Category: Journals (General) Authors: Correll, C. U., Manu, P., Olshanskiy, V., Napolitano, B., Kane, J. M., Malhotra, A. K. Tags: Nutritional and Metabolic Disorders, Lipids and Lipid Disorders, Metabolic Diseases, Pediatrics, Adolescent Medicine, Psychiatry, Adolescent Psychiatry, Child Psychiatry, Psychopharmacology, Schizophrenia, Drug Therapy, Adverse Effects Original Contribu Source Type: journals

Kids Are Gaining Weight on Medications TooEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study tackles two issues - medication weight gain and research of side effects in children. During the study period of eleven weeks, the kids - each just starting treatment with an antipsychotic medication - gained 10 to 20 pounds. From what I've gathered, all 205 of the kids gained weight - 100% of them. Ouch! Why the weight gain with these meds? Researchers are not exactly sure, but believe it is probably related to increased appetite, changes in how the body metabolizes sugar and decreases in activity due to sedation. Tanner reports, "The study authors said their results show that children on the drugs should be...
Source: About.com Bipolar Disorder - October 26, 2009 Category: Psychiatry Source Type: consumer

[Tics and Tourette's syndrome throughout the life span.]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Chronic motor and vocal tics lasting longer than a year are classified as Tourette's syndrome (TS). Tics mostly manifest before the age of 11 years. Boys are affected at a threefold higher rate than girls. Tics are often worst at the age of 14; in 50% of the cases the tic symptoms will remit nearly completely. Severely affected patients often suffer from comorbidities. In childhood and adolescence the most common comorbid condition is attention deficit hyperactivity disorder (ADHD). Obsessive-compulsive behaviour, anxiety and affective disorder might occur in the course of TS. A dysregulation in the dopaminergic neurot...
Source: Der Nervenarzt - October 25, 2009 Category: Neurology Authors: Neuner I, Ludolph A Tags: Nervenarzt Source Type: journals

Dissociable Control of Impulsivity in Rats by Dopamine D2/3 Receptors in the Core and Shell Subregions of the Nucleus AccumbensEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Dissociable Control of Impulsivity in Rats by Dopamine D2/3 Receptors in the Core and Shell Subregions of the Nucleus Accumbens Neuropsychopharmacology advance online publication, October 21, 2009. doi:10.1038/npp.2009.162 Authors: Morgane Besson, David Belin, Ruth McNamara, David EH Theobald, Aude Castel, Victoria L Beckett, Ben M Crittenden, Amy H Newman, Barry J Everitt, Trevor W Robbins & Jeffrey W Dalley Keywords: impulsivity, 5-CSRT task, NAcbs, DA receptors, nafadotride, aripiprazole (Source: Neuropsychopharmacology)
Source: Neuropsychopharmacology - October 20, 2009 Category: Neurology Authors: Morgane BessonDavid BelinRuth McNamaraDavid EH TheobaldAude CastelVictoria L BeckettBen M CrittendenAmy H NewmanBarry J EverittTrevor W RobbinsJeffrey W Dalley Source Type: journals

A Systematic Review of Cardiovascular Effects After Atypical Antipsychotic Medication OverdoseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
2.5 out of 5 stars A SYSTEMATIC REVIEW OF CARDIOVASCULAR EFFECTS AFTER ATYPICAL ANTIPSYCHOTIC MEDICATION OVERDOSE. Tan HH et al. Amer J Emerg Med 2009;27:607-616. Abstract This is a review of cardiovascular effects reported in published cases of overdose from 5 atypical antipsychotic medications (AAPMs): aripiprazole (Abilify), olanzapine (Zyprexa), quetiapine (Seroquel), risperidone (Risperdal), and ziprasidone (Geodon). Although the results are skewed by publication bias and incomplete information, the authors interpret the data as suggesting that AAPM overdose is unlikely to cause significant cardiotoxicity. How...
Source: The Poison Review - October 19, 2009 Category: Toxicology Authors: Leon Tags: Medical atypical antipsychotic cardiovascular Source Type: info

Aripiprazole versus other atypical antipsychotics for schizophreniaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: Cochrane Library Area: Evidence > Drug Class Focused Reviews Background In many countries of the industrialised world second generation (atypical) antipsychotics have become first line drug treatments for people with schizophrenia. The question as to whether, and if so how much, the effects of the various second generation antipsychotics differ is a matter of debate. In this review we examine how the efficacy and tolerability of aripiprazole differs from that of other second generation antipsychotics. Objectives To evaluate the effects of aripiprazole compared with other atypical antipsychotics for peo...
Source: NeLM - Drug Class Focused Reviews - October 15, 2009 Category: Drugs & Pharmacology Source Type: organizations

Antipsychotic effects on auditory sensory gating in schizophrenia patientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: P50 sensory gating deficit has repeatedly been demonstrated in schizophrenia. Studies have produced inconsistent findings with respect to normalization of P50 gating in patients with schizophrenia receiving treatment with different antipsychotics. The current study was designed to determine whether there is a difference in P50 gating in schizophrenia patients treated with first-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs), including clozapine. P50 evoked potential recordings were obtained from 160 patients with schizophrenia and 77 healthy comparison subjects. Forty-three patients ...
Source: European Neuropsychopharmacology - October 15, 2009 Category: Psychiatry & Psychology Authors: Eva María Sánchez-Morla, José Luis Santos, Ana Aparicio, María Ángeles García-Jiménez, Clara Villanueva, Vicente Martínez-Vizcaíno, Celso Arango Tags: Research papers Source Type: journals

[Aripiprazole and acute dystonia.]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The case of a patient who developed acute dystonia during treatment with aripiprazole prompted us to review the literature for reports on similar cases. From the literature we conclude that aripiprazole has a favourable profile as far as extrapyramidal side effects are concerned. However, the reports on extrapyramidal side effects in the literature may be incomplete. It is therefore still important that such cases are reported within the framework of post-marketing surveillance. PMID: 19821245 [PubMed - in process] (Source: Tijdschrift voor Psychiatrie)
Source: Tijdschrift voor Psychiatrie - October 14, 2009 Category: Psychiatry Authors: Komen G, Van Den Eede F, Dom G Tags: Tijdschr Psychiatr Source Type: journals

Aripiprazole: Dystonia and akathisia: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - October 12, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Aripiprazole: First report of acute myopia: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - October 6, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Table of ContentsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Study Examines Impact of Treatment on Prodromal Symptom Progression in YouthTargeted Naltrexone Reduces Alcohol Use Among Male Problem DrinkersRhabdomyolysis After Clozapine and Lithium TreatmentMetabolic Assessment of Adjunctive Aripiprazole in MDDCognitive Effects of Lorazepam in APOE [epsiv]4 CarriersProdromal Treatment StudiesElevated Rate of Adverse Events With QuetiapineA Case of Myopathy Associated With Valproic AcidNew Approvals: Saphris (Asenapine) for Schizophrenia, Bipolar DisorderNew Approval: Intuniv (Guanfacine) for ADHD (Source: The Brown University Psychopharmacology Update)
Source: The Brown University Psychopharmacology Update - October 5, 2009 Category: Psychiatry Source Type: journals

Repeated aripiprazole administration attenuates cocaine seeking in a rat model of relapseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Discussion These findings support the possibility that repeated aripiprazole may be an effective therapeutic agent for the prevention of relapse in abstinent cocaine users. Based on its antipsychotic profile, aripiprazole may be particularly useful for individuals diagnosed with comorbid psychoses, such as schizophrenia or bipolar disorder. Content Type Journal ArticleCategory Original InvestigationDOI 10.1007/s00213-009-1671-8Authors Matthew W. Feltenstein, Medical University of South Carolina Department of Neurosciences 173 Ashley Avenue Charleston SC 29425 USAPhong H. Do, Medical University of Sout...
Source: Psychopharmacology - September 24, 2009 Category: Psychiatry Tags: Psychopharmacology Source Type: journals

Improvement in Pisa Syndrome and Tardive Dyskinesia Following Aripiprazole Treatment [LETTERS TO THE EDITOR]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: J Neuropsychiatry Clin Neurosci)
Source: J Neuropsychiatry Clin Neurosci - September 22, 2009 Category: Neurology Authors: Shan, J.-C., Tseng, M.-C. M. Tags: LETTERS TO THE EDITOR Source Type: journals

Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ).Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The low rate of response to antidepressants in treatment resistant depression (TRD) justifies studies of next-step therapies following a treatment failure. In TRD clinical trials, it is important to verify the accurate diagnosis of treatment resistance for all enrolled subjects using a reliable and valid instrument. Self-rated scales can reduce the impact of investigator bias and reduce the time burden for clinical researchers. The Massachusetts General Hospital (MGH) Antidepressant Treatment Response Questionnaire (ATRQ) is a self-rated scale used to determine treatment resistance in major depressive disorder (MDD). T...
Source: CNS Neuroscience and Therapeutics - September 20, 2009 Category: Neuroscience Authors: Chandler GM, Iosifescu DV, Pollack MH, Targum SD, Fava M Tags: CNS Neurosci Ther Source Type: journals

Duration of Pharmacotherapy with Long-Acting Injectable Risperidone in the Treatment of SchizophreniaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract Although long-acting injectable risperidone (LAIR) has been hypothesized to improve medication adherence compared to oral medications, data from real-world practice have yet to be presented on time to treatment discontinuation. Records of all new prescriptions for antipsychotic medication during the first 2 months of FY 2006 for VA patients diagnosed with schizophrenia (N = 11,821) were examined and duration of treatment with LAIR and oral antipsychotics were calculated for the next 2 years. Multivariable logistic regression was used to identify patient characteristics independen...
Source: Psychiatric Quarterly - September 19, 2009 Category: Psychiatry Tags: Psychiatric Quarterly Source Type: journals

Comparison of the mGlu(5) receptor positive allosteric modulator ADX47273 and the mGlu(2/3) receptor agonist LY354740 in tests for antipsychotic-like activity.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion, in selected rodent models for positive schizophrenia symptoms, ADX47273 showed better efficacy than LY354740. PMID: 19765575 [PubMed - as supplied by publisher] (Source: European Journal of Pharmacology)
Source: European Journal of Pharmacology - September 14, 2009 Category: Drugs & Pharmacology Authors: Schlumberger C, Pietraszek M, Gravius A, Klein KU, Greco S, Morè L, Danysz W Tags: Eur J Pharmacol Source Type: journals

Comparative Utility of Aripiprazole and Haloperidol in Schizophrenia: Post Hoc Analysis of Two 52-Week, Randomized, Controlled TrialsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Applied Health Economics and Health Policy)
Source: Applied Health Economics and Health Policy - September 7, 2009 Category: Health Management Authors: Kane, John M.Kim, EdwardKan, Hong J.Guo, ZhenchaoBates, John A.Whitehead, RichardPikalov, Andrei Tags: Original Research Articles Source Type: journals

Aripiprazole: Tardive dyskinesia and akathisia: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - August 31, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

The Mothers Act Disease Mongering Campaign - Part IVEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This article says Courtenay publishes a website about "postpartum depression among dads" called "www.saddaddy.com." However, when clicking on the saddaddy link, PostpartumMen comes up today.And surely by coincidence, Courtenay will soon have a new book for sale titled, "Sad Dads," which he is currently writing, according to his bio on the consulting firm's website."If you'd like to arrange an individual consultation with Dr. Courtenay, please call 415-346-6719," the PostpartumMen website states.And apparently postpartum depression in dads is catchy. "If you're experiencing PPND, it increases the likelihood that your partne...
Source: NaturalNews.com - August 27, 2009 Category: Consumer Health Advice Source Type: news

An Open-Label Study of Aripiprazole: Pharmacokinetics, Tolerability, and Effectiveness in Children and Adolescents with Conduct DisorderEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Journal of Child and Adolescent Psychopharmacology Aug 2009, Vol. 19, No. 4: 431-439. (Source: Journal of Child and Adolescent Psychopharmacology)
Source: Journal of Child and Adolescent Psychopharmacology - August 24, 2009 Category: Pediatrics Tags: article Source Type: journals

Open Label Aripiprazole in the Treatment of Youth with Tic DisordersEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Journal of Child and Adolescent Psychopharmacology Aug 2009, Vol. 19, No. 4: 441-447. (Source: Journal of Child and Adolescent Psychopharmacology)
Source: Journal of Child and Adolescent Psychopharmacology - August 24, 2009 Category: Pediatrics Tags: article Source Type: journals

[A new approach to antischizophrenic therapeutics: D2 dopamine receptor partial agonists.]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Since chlorpromazine was described, antischizophrenic therapeutics have been enriched with various other D2 dopamine receptors antagonists, either neuroleptics (which develop extrapyramidal side effects) or non neuroleptic antipsychotics (devoid of extrapyramidal side effects when used at effective doses against psychotic expressions). The latter drugs display such properties on account of several associated pharmacological activities (D3 receptors antagonism more efficient than D2 antagonism; antagonism at cholinergic muscarinic receptors; antagonism at 5HT2 serotonin receptors). All these antipsychotic drugs are not,...
Source: Annales Pharmaceutiques Francaises - August 24, 2009 Category: Drugs & Pharmacology Authors: Costentin J Tags: Ann Pharm Fr Source Type: journals

Antipsychotics in pregnancyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This article summarizes the literature relating to the use of antipsychotics in pregnancy with a focus on the most commonly used atypical antipsychotics. Discusses other key factors to be considered when using these medications in pregnant or lactating women. Recognizes the contribution of pregnancy registers in gathering data to provide guidance to clinicians about the psychopharmacological management of women with serious mental illness. Women who are pregnant and who have a history of psychosis are commonly managed with antipsychotic medications. The evidence regarding the use of antipsychotics in pregnancy has been ins...
Source: Journal of Psychiatric and Mental Health Nursing - August 23, 2009 Category: Nursing Authors: K. MCCAULEY-ELSOM, C. GURVICH, S. J. ELSOM, J. KULKARNI Source Type: journals

Aripiprazole: Dose-Response Relationship in Schizophrenia and Schizoaffective DisorderEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: CNS Drugs)
Source: CNS Drugs - August 21, 2009 Category: Neurology Authors: Mace, ShubhraTaylor, David Tags: Review Articles Source Type: journals

[Diabetes and second-generation (atypical) antipsychotics.]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Schizophrenia is a common psychiatric illness (1% of the general population), characterized by the association of positive and negative symptoms and cognitive disorders. Antipsychotics, typical or atypical, are known to induce in patients with schizophrenia weight gain and abnormalities in glucose and lipid metabolisms. These modifications, in addition to metabolic risk factors, intrinsic to the psychiatric illness (physical inactivity, smoking, diabetes), increase the risk of cardiovascular complications. Some antipsychotics are associated with a higher risk of metabolic disorders. Before starting such a medication, a...
Source: Annales d'Endocrinologie - August 20, 2009 Category: Endocrinology Authors: Chabroux S, Haffen E, Penfornis A Tags: Ann Endocrinol (Paris) Source Type: journals

Aripiprazole: Tardive dyskinesia: 2 case reportsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - August 17, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Evidence for the Partial Dopamine-Receptor Agonist Aripiprazole as a First-Line Treatment of Psychosis in Patients With Iatrogenic or Tumorogenic Hyperprolactinemia [REVIEW ARTICLES]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: These findings suggest that aripiprazole may play an important niche role in treating psychotic patients sensitive to elevated prolactin and patients with prolactin-secreting pituitary tumors. (Source: Psychosomatics)
Source: Psychosomatics - August 16, 2009 Category: Psychiatry & Psychology Authors: Hoffer, Z. S., Roth, R. L., Mathews, M. Tags: Atypical Neuroleptics, Syndromes Secondary to General Medical Disorders REVIEW ARTICLES Source Type: journals

Tardive dyskinesia in a patient treated with quetiapine.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We report the case of a female patient with the diagnosis of schizoaffective disorder (using DSM-IV-TR criteria) who initially received amisulpride for 3 months, discontinued gradually because of persistent and distressing extra-pyramidal symptoms, and who developed tardive dyskinesia 3 months later after the initiation of quetiapine. A trial with ziprasidone resulted in a further worsening of tardive dyskinesia symptoms. A further trial with aripiprazole, improved her tardive dyskinesia symptoms. Although, it is under consideration the possibility that the improvement could have been due to the discontinuation of quetiapi...
Source: The World Journal of Biological Psychiatry - August 14, 2009 Category: Psychiatry Authors: Rizos E, Douzenis A, Gournellis R, Christodoulou C, Lykouras LP Tags: World J Biol Psychiatry Source Type: journals

Using oral ziprasidone effectively: the food effect and dose-response.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Ziprasidone is a newer "atypical" or "secondgeneration" antipsychotic. Oral ziprasidone (zipras idone hydrochlor ide) has been approved by the US Food and Drug Administration (FDA) for the treatment of schizophrenia, and acute manic or mixed episodes associated with bipolar disorder (with or without psychotic features). Comparisons with other second-generation antipsychotics in meta-analyses reveal similar efficacy to that observed for quetiapine or aripiprazole, but inferior efficacy to that of olanzapine or risperidone in the treatment of schizophrenia. However, the rate of dose titration and the dose achieved may ha...
Source: Advances in Therapy - August 7, 2009 Category: Drugs & Pharmacology Authors: Citrome L Tags: Adv Ther Source Type: journals

ABILIFY (Aripiprazole) Tablet ABILIFY (Aripiprazole) Solution ABILIFY (Aripiprazole) Tablet, Orally Disintegrating ABILIFY (Aripiprazole) Injection, Solution [Otsuka America Pharmaceuticals Inc]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Updated Date: Aug 7, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - August 7, 2009 Category: Drugs & Pharmacology Source Type: organizations

Global benefit-risk analysis of adjunctive aripiprazole in the treatment of patients with major depressive disorderEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study quantified the overall merit of adjunctive aripiprazole in major depressive disorder (MDD).Global benefit-risk (GBR) analysis quantified the benefit and risk differences between adjunctive aripiprazole and antidepressant (ADT) monotherapy. Three hundred and fifty six patients receiving ADT monotherapy and 366 patients receiving ADT and adjunctive aripiprazole (2-20 mg/day) were included. Efficacy measures included the Montgomery-Åsberg depression rating scale (MADRS) Total score response ([ge]50% reduction) and remission (response plus Total score [le] 10). Treatment-emergent adverse events were classified by s...
Source: Pharmacoepidemiology and Drug Safety - August 5, 2009 Category: Drugs & Pharmacology Authors: Stephen R. Wisniewski, PhD, Chi-Chang Chen, PhD, Edward Kim, MD, MBA, Hong J. Kan, PhD, Zhenchao Guo, PhD, Berit X. Carlson, PhD, Quynh-Van Tran, Pharm D, BCPP, Andrei Pikalov, MD, PhD Source Type: journals

Aripiprazole: Hiccups: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - August 3, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Focus on Aripiprazole: A Review of its use in Child and Adolescent Psychiatry.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: Aripiprazole may represent an important alternative for some children and adolescents who have experienced poor efficacy or significant metabolic adverse effects with their current antipsychotic treatment regimen. PMID: 19718428 [PubMed - in process] (Source: Journal of the Canadian Academy of Child and Adolescent Psychiatry)
Source: Journal of the Canadian Academy of Child and Adolescent Psychiatry - July 31, 2009 Category: Psychiatry Authors: Greenaway M, Elbe D Tags: J Can Acad Child Adolesc Psychiatry Source Type: journals

Abilify (Aripiprazole) - updated on RxListEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abilify (Aripiprazole) drug description - FDA approved labeling for prescription drugs and medications at RxList (Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 31, 2009 Category: Drugs & Pharmacology Source Type: consumer